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recipients of 4-6/6 HLA match grafts when at least 1.7  105
CD34 cells/kg are infused. This association was based on the
CD34 counts assessed on thawed products. But the question to be
addressed is indeed whether we can predict the thawed CD34 cell
dose based on an analysis of the pre-freeze CD34 enumeration
and the reliability of a CD34 assessment using an associated
aliquot. Therefore, we evaluated ﬁfty duplicate cryopreserved CB
aliquots (1.5 ml cryovials) from CB units stored according to the
standard banking procedures at the Madrid CBB (MCBB). After
shipment using a transport liquid nitrogen container, the aliquots
were thawed and processed by the same protocol at both the UM
and MCBB. Total pre-freezing NC/ml was 8.21  3.36  106.
Post-thaw counts at UM (6.77  2.92  106) and Madrid (6.49 
3.0  106) indicated equivalent NC recoveries (83  13% and 79
 15%, respectively). Cell viability by trypan blue before freezing
was 90  8%. However, there was a large difference between the
post-thaw viabilities at the UM (52  10%) and MCBB (81 
11%), indicating this technique is far from normalization. Simi-
larly, different CFU-GM scoring criteria at the UM and MCBB
(counting all CFU-GM colonies made up of greater than 40 or 20
cells, respectively) gave a lower CFU-GM number at UM vs.
MCBB (7.6  5.6 vs. 20.3  13.6/50000 cells plated). Despite this
variable readout, a signiﬁcant correlation between these values (r
0.7) was probably related to the consistency of the method and the
same culture media used in this study. The CD34 frequencies
(analyzed according to the ISHAGE dual-platform protocol) were
also discrepant. While the post-thaw %CD34 was 0.98  0.66 at
the UM, it was 0.57  0.39 at the MCBB (with the pre-freeze
%CD34 being 0.35  0.22). Bland-Altman and Intraclass Corre-
lation tests displayed considerable lack of agreement and no con-
sistent bias was observed between post-thaw CD34 at UM and
either pre-freeze or post-thaw CD34 values at MCBB. Thus, the
CD34 cell analysis at the UM and MCBB could not be used
interchangeably. However, linear regression showed a signiﬁcant
relationship (p  0.001). The linear equations estimated for each
prediction model were: i) y  2.758x  0.03121 (post-thaw [pt]
UM from pre-freeze [pf] MCBB counts); ii) y 1.534x 0.111 (pt
UM from pt MCBB counts); and iii) y  1.684x  0.00567 (pt
MCBB from pf MCBB counts). The coefﬁcient of determination
(R2a) for each model was 0.85, 0.82 and 0.80 respectively. There-
fore, as high as 85% and 82% of the total variance of post-thaw
CD34 values at the UM was explained respectively by the varia-
tion in pre-freeze (ﬁrst model) or post-thaw (second model) CD34
values at the MCBB. Importantly, all but one of the observed
CD34 counts were above the lower 90% individual prediction
limits. In summary, regardless the variability of CD34 cell enu-
meration at the UM and MCBB, it is possible to foresee with a
conﬁdence of 95% the CD34 cell dose that would be infused to
CB transplantation patients at the UM, either from the pre-freeze
MCBB data or from the CD34 assessment using a cryopreserved
aliquot. Whereas this regression model is only valid between the
UM and MCBB, this approach could be widely applied to predict
the transplantation outcomes from CD34 data provided by all CB
banks. Finally, on examination of the ﬂow cytometry data ﬁles, the
CD34 enumeration discrepancy was seemingly due to differences
in the initial cell acquisition performed at the UM and MCBB.
This discrepancy could be minimized by adopting uniform oper-
ating procedures.
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STANDARDIZATION OF CFU ASSAYS
Clarke, E., Atkinson, E.A. StemCell Technologies Inc., Vancouver, BC,
Canada
The advantages of using cord blood derived cells for the treat-
ment of leukemia and other hematological malignancies are now
well recognized. A recent regulatory ruling has mandated that a
functional test (e.g. a colony forming cell (CFC) assay) evaluating
the proliferative potential of the cells within the product following
cell processing and freezing must be performed if the sample is to
be used for transplantation. This highlights the need for a stan-
dardized assay. Previously published data have reported signiﬁcant
variability in the quantiﬁcation of the hematopoietic progenitors
using the CFC assay. Originally, recognition and enumeration of
the colonies was believed to account for this variability, however
variation in CFC quantiﬁcation could also be caused by different
media formulations or technical errors in sample preparation, cell
counting and dilution. Two distinct proﬁciency testing programs
were designed to assess the contribution of these various parame-
ters to the variability. The preliminary program, with 54 partici-
pants within North America, sought to determine the variability in
the recognition and enumeration of CFC. This was achieved by
determining the coefﬁcient of variation (CV) for CFU-GM and
total CFC enumeration when sample preparation events were
controlled. The second program was global, and also assessed the
contribution of the cell preparation steps to the overall variability
of the CFC assay. Participants (n  134) were provided with
identical vials of frozen bone marrow cells and were instructed to
thaw, wash, count, assess viability and dilute the cells prior to their
addition to a standardized formulation of MethoCult™. Fourteen
days later, participants quantiﬁed myeloid and erythroid colonies
as in the original tests. The considerable increase in the CVs in this
second test conﬁrmed that sample preparation steps contribute
signiﬁcantly to the variability in this assay. Standardized protocols
for cell preparation and training will decrease this variability and
facilitate global applicability of data generated from various labo-
ratories.
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UNRELATED CORD BLOOD TRANSPLANTATION IN PEDIATRIC PA-
TIENTS WITH NON-MALIGNANT DISEASES
Kurtzberg, J., Martin, P.L., Carter, S.L., Kernan, N.A., Sahdev, I.,
Wall, D., Pietryga, D., Wagner, J.E. The COLBT Steering Committee
The COBLT or Cord Blood Transplantation Study was a multi-
institutional study sponsored by the National Heart Lung and
Blood Institute. It was comprised of a banking and transplantation
study. The banking study established 3 banks which employed
common standards for donor screening and recruitment and cord
blood collection, processing, testing, cryopreservation and storage.
Screening of 34,700 women yielded 24,200 eligible for the study
who were approached for consent to participate. Eighty-ﬁve per-
cent (20,710 women) were consented and 17,207 were collected,
47% of which were discarded for low cell count, infectious disease
or maternal history exclusion or problems with processing. Of
note, a lower percentage of African American donations were
eligible for banking because they tended to have lower cell counts
per unit volume. Approximately 9112 units were moved to long
term storage and available for transplantation. The transplantation
study employed common protocols for preparative regimens,
GvHD prophylaxis and supportive care. Uniform deﬁnitions of
engraftment, GvHD and toxicity scoring, graft failure, causes of
death and relapse were employed. Strata were developed for chil-
dren and adults with malignant and non-malignant conditions.
This report focuses on outcomes in 69 patients with inborn errors
of metabolism transplanted between August of 1999 and June of
2004. The median age of the patients was 1.8 years (range 0.1-11.7
years). There was a predominance of males (55%) and Caucasians
(74%). The patients were diagnosed with MPS syndromes (57%),
ALD (12%), MLD (6%), Krabbe Disease (23%) and Tay Sachs
Disease (4%). Only 25% of patients were CMV seropositive before
transplant. A signiﬁcant portion of the patients (35%) had poor
performance status deﬁned by a Lansky score 80%. The
COBLT banks provided 70% of the donor units used in the study.
The median total nucleated cell dose and CD34 cell dose selected
were 8.7  107/kg and 2.4  105/kg, respectively. HLA matching
was performed using molecular typing at an intermediate resolu-
tion for HLA Class I A and B and high resolution for DRB1. High
resolution matching was scored retrospectively. The majority of
patients received grafts mismatched at 1 (45%) or 2 (48%) HLA
loci. After high resolution typing, 23% of patient/donor pairs were
demoted to lesser matches. Patients were prepared for transplant
with busulfan (16 doses with ﬁrst dose pharmacokinetics targeting
a steady state of 600-900 ng/ml), cyclophosphamide 200 mg/kg
and equine ATG 90 mg/kg. GvHD prophylaxis was delivered with
methylprednisolone and cyclosporine. The cumulative incidence
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of neutrophil engraftment, deﬁned as achieving and ANC of
500/L with 90% donor chimerism by day42 was 79% (95% CI
69-88%) and platelet engraftment, deﬁned as achieving an untrans-
fused count of 50,000/L by day 180 was 71% (95% CI 51-
74%). The cumulative incidence of Grade II-IV acute GvHD by
day 100 was 44% (95% CI 32-56%) and chronic GvHD by 1
year 23% (95% CI 8-27%). The cumulative incidence of overall
survival was 80% (95% CI 71-90%) and 72% (95% CI 61-83%) at
180 and 365 days, respectively. Recipient race, favoring Caucasian
[p  0.02], was the only parameter that impacted survival. HLA
matching by low or high resolution criteria did not impact survival.
Improved growth and cognitive function was seen in patients with
Hurler Syndrome and neonates transplanted with Krabbe disease.
Patients with presymptomatic ALD and juvenile MLD also did
well. Engraftment of donor cells was documented in heart and
brain in two patients studied at autopsy. In conclusion, unrelated
cord blood (UCB) represents an excellent stem cell source for
transplantation therapy for infants and young children with selec-
tive inborn errors of metabolism. UCB donors are readily available
and cord blood units generally contain more than sufﬁcient cell
doses for these younger and smaller patients. Newborn screening
for lysosomal and peroxisomal storage diseases would allow for
early diagnosis and maximally effective treatment.
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CORD BLOOD TRANSPLANTATION FOR CHILDREN WITH ACUTE LEU-
KEMIA: AN EUROCORD REGISTRY ANALYSIS
Gluckman, E. Hematology-Bone Marrow Transplant Department and
Eurocord ofﬁce, Hospital Saint Louis, Paris, France
Unrelated cord blood transplantation has been used to treat
patients with malignant and non-malignant hematopoietic disor-
ders for whom a HLA-compatible hematopoietic stem cell donor is
not available. The establishment of cord blood banks worldwide,
the increased number of cord blood units frozen and the shorter
time to ﬁnd a donor have made possible to use this source of
hematopoietic stem cells to treat more than 2 500 patients. The
Eurocord registry was established to study the clinical results of
cord blood transplantation and to compare the outcomes of unre-
lated transplants using either cord blood or bone marrow. Brieﬂy,
we have found in two distinct retrospective analyses concerning
children or adults with acute leukemia given either an unrelated
cord blood or bone marrow transplant, that leukemia free-survival
and relapse were similar in both types of graft (with adjustment for
confounding clinical factors). Cord blood recipients experienced
decreased incidence of acute graft-versus-host disease and delayed
hematopoietic recovery compared to bone marrow recipients. In
order to improve the delayed hematopoietic recovery after cord
blood transplantation, certain approaches have been investigated
such as ex-vivo expansion of cord blood cells, double cord blood
transplantation and reduced intensity conditioning regimen. We
have also attempted to establish some guidelines for cord blood
donor choice based on cord blood cell dose and number of HLA
disparities that have been found to be associated with hematopoi-
etic recovery.
Results of unrelated cord blood transplantation (UCBT) in
childhood acute myeloid leukemia: We analyzed 95 children
receiving UCBT for AML (20 in CR1, 47 in CR2 and 28 in more
advanced stage). Poor prognosis cytogenetic abnormalities were
identiﬁed in 29 cases. Most patients received a 1 or 2 HLA antigens
mismatched transplant. The median number of collected nucleated
cells (NC) was 5.2  107/kg. Cumulative incidence (CI) of neu-
trophil recovery was 78  4%, acute graft versus host disease
(GvHD) was 35  5% and 100-day transplant-related mortality
(TRM) was 20  4%. In multivariable analysis, a collected NC
dose higher than 5.2  107/kg was associated with a lower 100-day
TRM. The 2-year CI of relapse was 29  5% and was associated
with disease status. The 2-year LFS was 42  5%, (59  11% in
CR1, 50  8% in CR2, and 21  9% for children not in CR).
Children with poor prognosis cytogenetic features had similar LFS
compared to other patients (44  11% vs 40  8%). In CR2, LFS
was not inﬂuenced by the length of CR1 (53  11% in CR1 9.5
months compared to 50  12% in later relapses). We conclude
that UCBT is a good therapeutic for children with very poor
prognosis AML and who lack an HLA-identical sibling.
Results of unrelated cord blood transplant in children with
acute lymphoid leukemia: 195 patients with ALL were analyzed.
The median age at diagnosis was 4 years and at transplant 7 years.
The median follow-up time was 31 months. 35 patients were
transplanted in CR1 (with high risk cytogenetics abnormalities
85%), 85 in CR2, 45 in CR3 and 40 in relapse. 16 patients had
received a previous autologous or allogeneic transplant. The me-
dian number of nucleated cells infused was 3.8  107/kg, and the
median CD34 cell dose was 1.7  105/kg. The donor was HLA
identical in 21 cases, had 1/6 HLA differences in 80 cases, 2/6 HLA
differences in 78 cases and 3/6 HLA differences in 8 cases. Median
day to neutrophil engraftment was 29 days, median day to platelet
engraftment was 77 days. The cumulative incidence of neutrophil
engraftment at 60 days was 85%. It was dependent on the number
of nucleated cells infused. The incidence of GVH was low with
63% grade 0-1, 16% grade II, 12% grade III and 9% grade IV.
Estimate incidence of chronic GVH was 34%. Two-year trans-
plant related mortality was 39% in patients transplanted in CR and
58% in patients transplanted in relapse. In multivariate analysis, 3
factors were associated with an increasing probability of non-
leukemic death: advanced disease (p 0.04), previous transplant (p
 0.03) and centers performing less than 10 cord blood transplants
(p  0.0004). The cumulative incidence of relapse was 28%. The
predictive factors for relapse were: use of methotrexate for preven-
tion of GVH (p  0.02), longer time between diagnosis and CBT
(p  0.009), absence of acute GVH (p  0.002). Two-year DFS
was 36% in patients transplanted in CR and 15% in patients
transplanted in remission. Predictive factors increasing the proba-
bility of disease free survival were: remission status of the disease at
transplant (p  0.0006), previous transplant (p  0.0001), centers
performing less than 10 CBT (p  0.01). In conclusion, these
results show that unrelated HLA mismatched cord blood trans-
plant can cure a proportion of children with ALL who do not have
a bone marrow donor. The number of cells infused is a major
factor associated with hematopoietic recovery. The presence of
GVH is associated with a decreased risk of relapse. The center
effect is an important factor for survival probably in relation to the
selection of the patients (time to transplant) and donor choice
(number of cells infused).
Results of unrelated cord blood transplants compared to
unrelated bone marrow transplants in children with acute
leukemia: A multicenter retrospective analysis comparing the out-
come of unrelated cord blood transplant to unrelated bone marrow
transplants in children with acute leukemia was performed by
Eurocord and EBMT. Five hundred and ﬁfteen children with acute
leukemia receiving either an unrelated cord blood transplant
(UCBT, n  99) or an unrelated BMT (n  416) were analyzed.
Recipients of UCB were younger and had more pre-transplant
adverse disease factors. Most of the bone marrow donors were
HLA matched or had a maximum of 1 HLA difference while most
of the cord blood donors had 2 to 3 HLA differences. The median
number of nucleated cells infused was 4  108/kg in unrelated
BMT and 0.38  108/kg in unrelated UCBT. In unrelated BMT,
262 children received an unmanipulated BMT and 180 a T-cell
depleted BMT using Campath-1M as the most frequent means of
T-cell depletion. The median follow-up was 29 months. During
the ﬁrst 100 days after transplant, while unmanipulated and T-cell
depleted BMT did not differ in hematopoietic recovery and treat-
ment related mortality, the main ﬁndings that emerged from these
retrospective adjusted comparisons were the poor results of UCBT
concerning neutrophil and platelet recoveries and early transplant
related mortality. In contrast UCBT and T-cell depleted BMT
gave less acute GVHD than the unmanipulated BMT group. Fi-
nally the unmanipulated BMT and the UCBT groups had less
leukemic relapse than the T-cell depleted group. Considering the
long-term outcome, the unmanipulated BMT group had more
chronic GVHD than the T-cell depleted BMT and the UCBT
groups. Furthermore, while outcome in the 3 groups was compa-
rable in terms of long term relapse, mortality after day 100 was
increased in the T-cell depleted BMT group mostly because of the
occurrence during the ﬁrst 100 days post-BMT of early relapse and
infections. In summary, the main differences in adjusted outcomes
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